Maki Kobayashi

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Endoplasmic Reticulum Stress

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ayaka Asakawa, Ryoto Yoshimoto, Maki Kobayashi, Nanae Izumi, Takanori Maejima, Tsuneo Deguchi, Kazuishi Kubota, Hisashi Takahashi, Miyuki Yamada, Sachiko Ishibashi, Iichiroh Ohnishi, Yuko Kinowaki, Morito Kurata, Masashi Kobayashi, Hironori Ishibashi, Kenichi Okubo, Kenichi Ohashi, Masanobu Kitagawa, Kouhei Yamamoto
The Comprehensive Characterization of B7-H3 Expression in the Tumor Microenvironment of Lung Squamous Cell Carcinoma: A Retrospective Study. Cancers 16 (11) (2024)
Ayaka Asakawa, Ryoto Yoshimoto, Maki Kobayashi, Nanae Izumi, Takanori Maejima, Tsuneo Deguchi, Kazuishi Kubota, Hisashi Takahashi, Miyuki Yamada, Sachiko Ishibashi, Iichiroh Ohnishi, Yuko Kinowaki, Morito Kurata, Masashi Kobayashi, Hironori Ishibashi, Kenichi Okubo, Kenichi Ohashi, Masanobu Kitagawa, Kouhei Yamamoto
The Comprehensive Characterization of B7-H3 Expression in the Tumor Microenvironment of Lung Squamous Cell Carcinoma: A Retrospective Study. Cancers 16 (11) (2024)
Naoko Iida, Mitsuho Imai, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, Hiromichi Ebi, Hiroya Taniguchi, Norio Nonomura, Yu Sunakawa, Manabu Shiozawa, Kentaro Yamazaki, Shogen Boku, Hideaki Bando, Yuichi Shiraishi, Maki Kobayashi, Hiroki Goto, Akihiro Sato, Satoshi Fujii, Takayuki Yoshino, Yoshiaki Nakamura
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, Yoann Pradat, Agnes Ducoulombier, Barbara Pistilli, Thomas Bachelot, Frederic Viret, Christelle Levy, Nicolas Signolle, Alexia Alfaro, Diep T N Tran, Ingrid Judith Garberis, Hugues Talbot, Stergios Christodoulidis, Maria Vakalopoulou, Nathalie M Droin, Aurelie Stourm, Maki Kobayashi, Tomoya Kakegawa, Ludovic Lacroix, Patrick Saulnier, Bastien Job, Marc Deloger, Marta Jimenez, Thierry Petit, Vianney Baris, Pierre Laplante, Patricia L Kannouche, Virginie Marty, Magali Lacroix-Triki, Véronique Diéras, Fabrice Andre
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature medicine (2023)
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hiasto Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (2) (2021)